IDNA - MorphoSys May Not Recover From Adventurous Constellation Buyout May, 04 2022 05:16 PM iShares Genomics Immunology and Healthcare MorphoSys stock has taken a huge hit since its Constellation buyout. The company has staked an entire existing revenue stream for a development stage asset. The market hasn't taken this kindly. For further details see: MorphoSys May Not Recover From Adventurous Constellation Buyout